Rising Cancer Cases To Boost Predictive Biomarkers Market Growth: A Key Factor Shaping the Future of the Predictive Biomarkers Market in 2025

Which drivers are expected to have the greatest impact on the over the predictive biomarkers market's growth?
The predictive biomarkers market is expected to witness substantial growth due to an increase in cancer incidents. Cancer describes an illness where abnormal cells spread uncontrollably, potentially reaching other sections of the body. This escalation in cancer incidents is predominantly caused by aging populations, changing lifestyles, and greater exposure to factors such as tobacco, unhealthy food habits, and environmental pollutants. Predictive biomarkers pertaining to cancer facilitate in recognizing patients most likely to respond favorably to particular treatments, presenting more personalized and effective therapeutic options. For example, a report by the France-based International Agency for Research on Cancer (IARC), an agency of the World Health Organization (WHO) conducting cancer research, revealed in April 2024 that there were around 20 million new cancer incidents and roughly 10 million cancer-associated deaths in 2022. In addition, the report forecasts that the annual count of new cancer incidents may increase to 35 million by 2050, a 77% rise from 2022. Therefore, this escalation in cancer incidents will stimulate growth in the predictive biomarkers market.

Get Your Predictive Biomarkers Market Report Here:
https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

What is the future CAGR of the predictive biomarkers market, and how will it impact industry expansion?
In recent times, a consistent growth has been observed in the size of the predictive biomarkers market. The market, which was valued at $20.05 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 4.5% and reach $20.96 billion in 2025. Several factors contributed to this growth during the historic period. These include the surge in research and development investments, the enhancement of healthcare infrastructure, the development of partnerships between academic institutions and industry, the increasing prevalence of cancer and genetic disorders, and the escalating utilization of biomarkers in the process of drug development.

In the years ahead, the predictive biomarkers market is projected to experience consistent growth, escalating to a worth of $24.67 billion in 2029 with a compound annual growth rate (CAGR) of 4.2%. This growth during the forecast period can be traced back to the rising uptake of precision medicine, an amplified focus on preventative healthcare, escalating healthcare expenditure, an upswing in funding for biomarker-based diagnostics, the broadening of biobanks and tissue repositories, and increased global health consciousness. Cited trends in the forecast period encompass the involvement of artificial intelligence in biomarker evaluation, the evolution of non-invasive biomarker examination, progress in digital health tools based on biomarkers, breakthroughs in single-cell sequencing technologies, the expansion of real-time biosensing and monitoring systems, and advancements in bioinformatics tools capable of integrating data.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

What are the most significant trends transforming the predictive biomarkers market today?
In the predictive biomarkers industry, leading companies are concentrating on hastening biomarker development through innovative technological improvements, like AI-assisted biomarker identification, with the intent to secure a competitive advantage by introducing more individualized and effective treatments quicker. The utilization of AI in biomarker identification facilitates the examination of vast, intricate datasets, leading to the recognition of predictive biomarkers which may elude detection via conventional methods. One such example is the initiative by Scipher Medicine, Inc., a precision immunology enterprise based in the US, which launched PRoBeNet (Predictive Response Biomarkers using Network Medicine) in July 2024. The goal of this project is to hasten the progression of creating predictive response biomarkers, for intricate diseases, by combining AI and network biology. PRoBeNet pinpoints biomarkers of therapy response by consolidating therapy-targeted proteins and disease-specific molecular signatures. The technology has proven successful for autoimmune diseases like rheumatoid arthritis, ulcerative colitis, and Crohn's disease, and can also be employed in other intricate diseases and various drug development phases.

Which key market segments comprise the predictive biomarkers market and drive its revenue growth?
The predictive biomarkers market covered in this report is segmented -

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications
2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring
3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:
1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer
2) By Metabolic Disease: Type 1 and Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance
3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease
4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Immunodeficiency Disorders
5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20595

What regions are at the forefront of predictive biomarkers market expansion?
North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the leading players fueling growth in the predictive biomarkers market?
Major companies operating in the predictive biomarkers market are Johnson & Johnson Services Inc, F Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthcare GmbH, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Bio-Rad Laboratories Inc, QIAGEN GmbH, Almac Group Limited, ArcherDX Inc, Luminex Corporation, Guardant Health Inc, Meso Scale Diagnostics LLC, Myriad Genetics Inc, NanoString Technologies Inc, Fujirebio Inc, Asuragen Inc, Biognosys AG, Epigenomics AG, OncoCyte Corporation, Biomarker Technologies Inc

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp

What Is Covered In The Predictive Biomarkers Global Market Report?

•Market Size Forecast: Examine the predictive biomarkers market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the predictive biomarkers market for a structured understanding.
•Key Players Overview: Analyze major players in the predictive biomarkers market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the predictive biomarkers market.
•Segment Contributions: Evaluate how different segments drive overall growth in the predictive biomarkers market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the predictive biomarkers market.
•Industry Challenges: Identify potential risks and obstacles affecting the predictive biomarkers market.
•Competitive Landscape: Review strategic developments in the predictive biomarkers market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.